<DOC>
	<DOCNO>NCT01856036</DOCNO>
	<brief_summary>This protocol study impact cryoablation immune response patient diagnose invasive breast cancer small 1.5 cm . It profile immune response cryoablation invasive breast cancer . The intra-tumoral systemic immune response cryoablation determine compare pre-ablated breast cancer specimens historical control specimen .</brief_summary>
	<brief_title>Anti-Tumor Immunity Induced Cryoablation Invasive Breast Cancers</brief_title>
	<detailed_description>Patients small breast cancer undergo cryoablation breast cancer . Approximately six week cryoablation , definitive breast surgery perform . Blood drawn research cryoablation surgery regular follow-up visit . Blood tissue sample use determine immune response .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>1 . Subjects invasive breast cancer 1.5 cm less 2 . The breast cancer must ductal histology , unifocal , estrogen receptor positive her2/neu negative . 3 . The tumor must visible ultrasound subject must prior surgical resection primary lesion . 4 . A clip mark breast cancer must place time initial diagnosis place prior cryotherapy . 5 . The breast cancer must amenable cryoablation ( visible ultrasound 2 mm skin chest wall ) . 6 . Subjects metastatic disease diagnosis elect primary tumor excise eligible enrollment . 7 . For subject breast implant , treat physician must document adequate distance exist lesion implant ensure ablated lesion contact jeopardize implant . 8 . Subjects must able provide consent . 1 . Subjects breast cancer lobular histology , lymph vascular invasion extensive intraductal component exclude . 2 . Subjects multicentric multifocal breast cancer 3 . Subjects breast cancer invade skin significant skin tethering ( assess clinically ) . 4 . Subjects receive chemotherapy within one year undergo neoadjuvant chemotherapy exclude . 5 . Subjects metastatic disease diagnosis exclude unless elect definitive surgical therapy primary lesion . 6 . Subjects breast cancer amenable cryoablation ( lesion visible ultrasound , chest wall within 2 mm skin ) exclude . 7 . Subjects diagnose another malignancy precede 5 year exclude . 8 . Subjects diagnose simultaneous bilateral breast cancer . 9 . Subjects receive immunosuppressive therapy within 6 month include oral steroid exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ductal Histology</keyword>
	<keyword>Unifocal</keyword>
	<keyword>Estrogen Receptor Positive</keyword>
	<keyword>her2neu negative</keyword>
</DOC>